|
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). |
|
|
Honoraria - Ono Pharmaceutical |
Research Funding - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genentech; GlaxoSmithKline; Merck; Novartis |
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Patent Pending (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Millennium (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer |
Research Funding - Prometheus |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bayer; Novartis |
Research Funding - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Novartis |
|
|
Stock and Other Ownership Interests - Jounce Therapeutics |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Jounce Therapeutics; MedImmune |
|
|
Honoraria - Medivation; Novartis |
Consulting or Advisory Role - Aveo; Myriad Pharmaceuticals; Novartis; Pfizer |
Research Funding - Medivation |
|
|
No Relationships to Disclose |
|
Christian K. Kollmannsberger |
Honoraria - Novartis; Pfizer |
Consulting or Advisory Role - Novartis; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb (I) |
|
|
Employment - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Genentech |
Research Funding - AB Science; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Prometheus |